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Abstract  
 
The prevalence of methylphenidate and dextroamphetamine misuse and abuse was 
examined in 450 adolescents referred for substance abuse treatment.  Twenty three 
percent reported nonmedical use of these substances and six percent were diagnosed as 
methylphenidate or dextroamphetamine abusers.  Abuse was more common in 
individuals who were out of school and had an eating disorder.  Methylphenidate and 
dextroamphetamine abuse appears to be much less common than abuse of most other 
substances.  It does occur, however, and parents and schools need to exert greater control 
over the dispensing of these medications.  Physicians are advised to prescribe non-
stimulant medications (e.g., bupropion) when treating attention deficit hyperactivity 
disorder in substance-abusing individuals.   
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   Psychostimulants such as methylphenidate (Ritalin®), dextroamphetamine 
(Dexedrine®), and Adderall® are well established as effective treatments for attention 
deficit hyperactivity disorder1, 2, 3, 4.  They have potential risks, however, with one of the 
more important ones being the risk of drug abuse.  These medications are classified as 
Schedule II substances in the Controlled Substances Act, which contains medically 
prescribed substances with the highest abuse potential and dependence profile.   
However, considerable controversy exists about how serious a problem prescribed 
stimulant abuse actually is.  On the one hand, the Council on Scientific Affairs of the 
American Medical Association concluded that ‘‘there is little evidence that stimulant abuse 
or diversion is currently a major problem, particularly among those with ADHD’’5.  Another 
review reports ‘‘a nearly total absence of methylphenidate abuse reported in 
methylphenidate-treated children and adolescents in spite of its very widespread 
application’’6.  An even stronger statement is made in the Practitioners Guide to 
Psychoactive Drugs for Children & Adolescents 2nd ed., where it states, ‘‘There are no 
reported individual cases of addiction or serious drug dependence to date with these 
medications.’’7  Similar sentiments have been echoed elsewhere8,9. 
On the other hand, the U.S. Drug Enforcement Administration <DEA> has 
expressed serious concern about methylphenidate being diverted and abused.  This was 
first stated in an October 1995 press release10 and background paper11 that pointed out that 
methylphenidate ranks in the top 10 most frequently reported controlled pharmaceuticals 
stolen from licensed handlers.  These concerns were reiterated in congressional testimony 
to the Subcommittee on Early Childhood, Youth and Families in May 2000.  In this 
testimony the DEA indicated that methylphenidate has a high abuse liability and that the 
magnitude of methylphenidate diversion and trafficking is comparable to pharmaceutical 
drugs of similar abuse potential such as morphine12. 
There is good evidence that a small percentage of adolescents and young adults 
are using these substances for non-medical purposes.  In the national Monitoring the 
Future survey of high school students, the percentage of seniors reporting non-medical 
use of Ritalin® in the past year was .1 - .7% between 1976 and 1993; .8 - 1.2% between 
1994 and 1996; and 2.2 - 2.8% between 1997 and 200013.  A 1998 state-wide survey of 
Indiana students found that approximately 5% of students in grades 9-12 reported non-
medical use of Ritalin® in the past year, with 2.5% reporting non-medical use in the past 
month14.  In Canada, 6.3% of Ontario high school students reported past-year non-medical 
use of stimulants other than methamphetamine in 199415.   
However, it is unclear how much actual abuse and dependence is occurring.  By 
definition, substance abuse is a pattern of use leading to clinically significant impairment 
or distress as manifested by either failure to fulfil major role obligations; recurrent use in 
physically hazardous situations (e.g. driving); recurrent substance-related legal problems; 
or serious social or interpersonal problems16.  Abuse does occur, as evidenced by several 
case reports of regular use leading to medical problems or death17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28.  
Some of these case reports include individuals who were abusing their own 
prescriptions29, 30, 9.   
However, there is very little known about the general prevalence of 
methylphenidate abuse and dependence.  There are a few studies on treatment 
populations that shed some light on this issue.  Haglund and Howerton31 found that 59% of 
192 adult patients admitted to a drug abuse treatment program reported non-medical use 
of methylphenidate at some point, mostly in combination with opiates such as 
pentazocine31.  However, only 1.5% were using methylphenidate on a daily basis.  Raskin 
and Bradford32 reported that 18/40 methadone maintenance patients were regular 
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intravenous users of methylphenidate.  Marsh et al.33 found that 10.4% (24/231) of 
adolescents referred for an assessment at a community based alcohol/drug treatment 
facility in South Carolina between 1992 and 1996 reported non-medical use of 
methylphenidate.  No details were provided concerning frequency of use.   
Clearly, more research is needed to establish the actual prevalence of prescribed 
stimulant abuse.  The purpose of the present study is to investigate this issue in a group of 
substance-abusing adolescents with comorbid mental health problems.  Our first objective 
is to determine the prevalence of methylphenidate and dextroamphetamine misuse and 
abuse in this population.  Our second objective is to investigate characteristics that 
differentiate abusers from nonabusers.  This latter information will be particularly useful to 
physicians in their decisions about when to prescribe stimulants. 
 
Method 
The Addiction Centre is located at the Foothills Medical Centre, Calgary, Alberta, 
Canada.  It specializes in the assessment and treatment of substance-abusing adolescents 
with comorbid psychiatric conditions.  It is primarily an outpatient program, but a small 
percentage of patients are admitted to an affiliated inpatient unit.  All adolescents receive 
a comprehensive 3-4 hour assessment.  The assessment begins with an interview using 
the Adolescent Drug and Alcohol Diagnosis (ADAD), a structured questionnaire with 
established reliability and validity34, 35.  This interview is followed by urinalysis drug testing, 
and then the adolescent’s family is interviewed.  All interviews are conducted by a nurse, 
social worker or psychologist, while a family physician and an adolescent psychiatrist 
observe behind a 2-way mirror.  The psychiatrist makes diagnoses (current) at the end of 
the assessment, after reviewing the background file and information presented during the 
interviews.  An extensive 10 to 15- page report is produced from the assessment.   
A retrospective file review was conducted of the 450 adolescents seen at the 
Addiction Centre between January 1993 and May 1999.  Each assessment was read by the 
second and third authors (LG, MS-F) and information was extracted using a coding sheet 
with the following categories:  age, gender, race/ethnicity, school attendance, residency, 
psychiatric and substance use diagnoses (current), a list of all substances used (lifetime), 
and whether the adolescent had ever been prescribed methylphenidate or 
dextroamphetamine (Dexedrine® or Adderall®).  For all individuals who reported non-
medical use of methylphenidate or dextroamphetamine, information was also extracted 
concerning the method of administration, frequency of use, the length of time using, 
where they obtained the medication, and reasons for discontinuation. 
 The sample was divided into methylphenidate/dextroamphetamine abusers and 
nonabusers to investigate variables that differentiated the groups using a forward 
stepwise logistic regression.  ‘‘Abusers’’ were individuals who received a diagnosis of 
current methylphenidate or dextroamphetamine abuse at the time of the assessment.  
‘‘Non-abusers” were individuals who did not receive a diagnosis of current 
methylphenidate or dextroamphetamine abuse (although some of these individuals may 
have used these substances occasionally for non-medical purposes at some point in their 
lives (‘‘misusers’’) and some may have had a past history of methylphenidate or 
dextroamphetamine abuse).  
 
Results 
Age range of the sample was 12 to 18 years, with an average of 15.4.  Fifty-two 
percent were male, 82 percent were Caucasian, 69 percent were attending school, and 78 
percent were living at home.  The most common psychiatric diagnoses were Conduct 
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Disorder (26%), Major Depression (26%), Attention-Deficit Hyperactivity Disorder (25%), 
Oppositional Defiant Disorder (18%), Post-Traumatic Stress Disorder (17%), Dysthymia 
(15%), Substance-Induced Mood Disorder (11%), and Learning Disability (10%).   
Twenty three percent (105/450) of adolescents reported non-medical use of either 
methylphenidate or dextroamphetamine at some point in their lives (‘‘Misusers’’).  Of 
these 105 adolescents, 92 reported non-medical use of methylphenidate, 7 reported non-
medical use of dextroamphetamine (Dexedrine), and 6 reported non-medical use of both.  
The median number of times used was 3 (range 1 -- 700), and the median length of time 
used was 26 days (range 1 day -- 3 years).  Of the 87 adolescents ever prescribed 
methylphenidate or dextroamphetamine, 38/87 (44%) reported non-medical use.   
Six percent (26/450) of the sample was diagnosed as current methylphenidate or 
dextroamphetamine abusers (23 were methylphenidate abusers and 3 were 
methylphenidate and dextroamphetamine (Dexedrine) abusers).  The most common 
method of administration was crushing tablets and taking the drug intranasally.  The 
median number of times used was 80 (range 21 -- 700).  The median length of time using 
was 120 days (range 21 days -- 3 years).  The median frequency of use was daily (range 3 
times/week -- 5 times/day).  Twenty-two individuals reported where they obtained the 
medication:  41% (9/22) obtained it from their own prescription; 23% (5/22) from the street; 
23% (5/22) from a friend’s prescription; and 15% (4/26) from a sibling’s prescription.    
For comparison purposes, Table 1 lists the reported lifetime use and current abuse 
of all substances.  As can be seen, methylphenidate and dextroamphetamine were both 
the 7th most commonly used and abused substances.   
<Insert Table 1 here> 
An SPSS forward stepwise logistic regression investigated characteristics 
differentiating individuals with diagnosed methylphenidate/dextroamphetamine abuse 
and those without this diagnosis.  Variable entry order was determined by the size of the 
Wald statistic, with a minimum entry level of p = .05 and a removal level of p = .10.  Thirty-
two demographic, psychiatric, and substance use predictor variables were used.  After 
deletion of 5 cases with missing values, data from 445 adolescents were available for 
analysis:  26 abusers and 419 nonabusers.   
Maximal discrimination between the groups occurred with a constant and only two 
predictor variables:  being in school and having an eating disorder.  Abusers were 
significantly more likely to be out of school and to have an eating disorder.  A test of the 
full model with the two predictors against a constant-only model was statistically reliable, 
χ2 (2, N = 445) = 12.1, p < .005, indicating that the two predictors reliably distinguished 
between abusers and nonabusers.  The variance accounted for was small, however, with 
Nagelkerke R squared = .075.  Overall prediction success was 93.8%.  Table 2 lists the 
demographic and psychiatric characteristics of the two groups as well as the Wald 
statistics for each of these variables.  Table 3 lists the substance use characteristics of the 
two groups and the Wald statistics for these variables. 
<Insert Table 2 here> 
<Insert Table 3 here> 
 
Discussion 
 The present study found that 23% of adolescents referred for a substance-abuse 
assessment at an outpatient clinic reported non-medical use of methylphenidate or 
dextroamphetamine at some point in their lives.  Most of these individuals misused these 
substances a few times on a few occasions.  However, a small portion of the sample used 
on a much more frequent and sustained basis.  Six percent of the total sample was 
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diagnosed as methylphenidate or dextroamphetamine abusers at the time of the 
assessment.   
 Our results indicate that for this population, prescription stimulant abuse is neither 
at crisis proportions nor is it a nonexistent problem.  It is clear that prescribed stimulants 
are misused and abused.  However, it is also clear that the misuse and abuse is not 
occurring on the same scale as other substances.  Methylphenidate and 
dextroamphetamine were the seventh most commonly used substances after alcohol, 
cannabis, hallucinogens, cocaine or crack, over-the-counter drugs (non-medical use), and 
methamphetamine; and the seventh most commonly abused substances after alcohol, 
cannabis, hallucinogens, cocaine or crack, inhalants, and methamphetamine.  To further 
put this in perspective, although there were 1,478 emergency room mentions of 
methylphenidate in the Drug Abuse Warning Network in 1999, there were 168,763 
mentions of cocaine5 (although it should be noted these statistics refer to all mentions, not 
just adolescents). 
 The rate of methylphenidate/dextroamphetamine misuse is roughly four times 
higher than the rate of abuse.  It is fairly typical that a much higher percentage of 
individuals experiment with a drug than abuse the drug.  However, it is worth noting that 
in the present study only phencyclidine, over-the-counter drugs, minor tranquilizers, and 
barbiturates had a higher ratio of misusers to abusers.  Anecdotal evidence suggests that 
although methylphenidate is widely available and fairly inexpensive, it is not often a first 
choice of adolescent substance users because of its status as a synthetic medication.  It 
should also be noted that although methylphenidate can produce comparable levels of 
‘‘high’’ or ‘‘rush’’ compared to cocaine36, it is cleared from the brain much more slowly, 
which tends to be associated with less subsequent craving37.    
 There were very few demographic, psychiatric or substance use characteristics 
significantly differentiating abusers from nonabusers.  The exception to this was school 
attendance and having a concurrent eating disorder.  Abusers were significantly less likely 
to be attending school (41% attending versus 71% of nonabusers).  This may be because 
methylphenidate/dextroamphetamine abuse makes ongoing school attendance more 
difficult.  Or, it may be that methylphenidate/dextroamphetamine abuse and school 
absenteeism are both manifestations of more severe problems.  The increased likelihood 
of abusers having an eating disorder (11% versus 2% of nonabusers) is likely because the 
decreased appetite and weight loss associated with these medications makes them 
appealing to individuals trying to control their weight. 
 
Limitations 
 The main limitation of this study is that the sample is not representative of 
substance-abusing adolescents generally, as it contains a greater proportion of dually-
diagnosed individuals. Roughly 95% of individuals in the present study had a co-occurring 
psychiatric disorder, compared to approximately 50% in the general population of 
substance-abusing adolescents38.  However, in all other respects the demographics of our 
sample appears to be similar to what is found in the general adolescent treatment 
population39,40 and in the general adolescent substance-abusing population41.  The present 
study also does not address the abuse of these substances in substance-using adults, 
which may be much higher or lower.  A final limitation is that ascertainment of substance 
use was based primarily on self-report.  Although the accompanying urinalysis helped 
ensure valid report at the time of the assessment, it did not ensure validity of the historical 
reports given. 
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Clinical Implications 
 Psychostimulants are effective treatments for attention deficit hyperactivity 
disorder.  However, they do have risks, with one of the more important ones being the risk 
of misuse and abuse.  Although not directly tested, the present results suggest that the 
most important risk factor for methylphenidate/dextroamphetamine misuse and abuse is 
the abuse of other substances (i.e., only 2% of senior high school students in the latest 
Monitoring the Future study misused prescribed stimulants versus 23% of substance 
abusing adolescents in the present study).  Substance abusing adolescents who are out of 
school and/or have a concurrent eating disorder appear to have an even higher risk.    
 Thus, routine screening for substance abuse and eating disorders is a sensible 
precaution that should occur before any medication is prescribed.  Furthermore, 
considering the efficacy of certain non-stimulant medications for attention deficit 
hyperactivity (e.g., bupropion)42,43, it is recommended that non-stimulant medications be 
used as a first line pharmacological treatment for these higher risk groups. 
 Although physicians need to be cautious about to whom they prescribe 
psychostimulants, parents have an even more important role to play.  In the present study, 
roughly three-quarters of the methylphenidate and dextroamphetamine abused came 
from the adolescent’s own prescription or the prescription of a friend or sibling.  The risk 
of psychostimulant abuse could be substantially reduced if parents became more aware of 
the abuse potential of prescription stimulants and exerted greater control over the 
dispensing of these medications.  
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Table 1 
 
Lifetime Use and Current Abuse of Substances for the Entire Sample 
 
 Lifetime 
Use 
Current 
Abuse 
Alcohol 98% 80% 
Cannabis 96% 85% 
Hallucinogens 79% 46% 
Cocaine or Crack 38% 18% 
Over-the-Counter Drugs (non-medical use) 27% 6% 
Methamphetamine 24% 7% 
Methylphenidate/Dextroamphetamine (non-medical 
use)
23% 6% 
Inhalants 17% 9% 
Prescription Opiates (non-medical use) 17% 6% 
Phencyclidine 17% 4% 
Nonprescription Opiates 9% 4% 
Minor Tranquilizers (non-medical use) 7% 1% 
Barbiturates 2% 0% 
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Table 2 
 
Demographic and Psychiatric Characteristics of Methylphenidate/Dextroamphetamine 
Abusers and Non-Abusers 
 
 
 
 
1 Wald statistics following entry of the two significant variables into the forward stepwise  
 
logistic regression.  All Wald statistics were nonsignificant unless otherwise noted.
 
Abusers  
(n=26) 
Non-
Abusers 
(n=424) 
Wald 
Statistic1 
In school 41% 71% 7.3 p < .01 
Caucasian 74% 82% 1.7 
Male 43% 52% 1.3 
Living at home 77% 78% .3 
Age 15.6 15.4 .2 
Eating Disorder 11% 2% 8.4 p < .01 
Substance-Induced Mood 
Disorder
21% 11% 3.2 
Major Depression 43% 25% 2.7 
ADHD 36% 24% 2.1 
Dysthymia 7% 15% 1.3 
Learning Disability 4% 10% 1.1 
Bipolar 4% 1% .5 
Mental Retardation 0% 2% .5 
Schizophrenia 0% 1% .4 
Panic Disorder 0% 1% .4 
Generalized Anxiety 0% 2% .3 
Conduct Disorder 25% 26% .2 
Oppositional Defiant Disorder 18% 18% .1 
Post-Traumatic Stress Disorder 18% 17% 0 
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Table 3 
 
Concurrent Substance Abuse by Methylphenidate/Dextroamphetamine Abusers and Non-
Abusers 
 
 
Abusers  
(n=26) 
Non-
Abusers 
(n=424) 
Wald 
Statistic1 
Phencyclidine Abuse 11% 4% 3.2 
Nonprescription Opiate Abuse 11% 4% 2.8 
Methamphetamine Abuse 14% 6% 2.4 
Prescription Opiate Abuse 14% 6% 1.9 
Other Prescription Drug Abuse 4% 3% 1.4 
Cocaine/Crack Abuse 32% 18% .8 
Inhalant Abuse 4% 10% .7 
Hallucinogen Abuse 54% 46% .3 
Over-the-Counter Drug Abuse 4% 6% .3 
Minor Tranquilizer Abuse 0% 1% .2 
Cannabis Abuse 85% 85% 0 
Alcohol Abuse 79% 81% 0 
Barbiturate Abuse 0% 0% 0 
# Substances Abused 3.1 2.7 1.6 
 
 
 
1 Wald statistics following entry of the two significant variables into the forward stepwise  
 
logistic regression.  All Wald statistics were nonsignificant unless otherwise noted. 
